PRMS
MCID: PRG090
MIFTS: 32

Progressive Relapsing Multiple Sclerosis (PRMS)

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Progressive Relapsing Multiple Sclerosis

MalaCards integrated aliases for Progressive Relapsing Multiple Sclerosis:

Name: Progressive Relapsing Multiple Sclerosis 12 15
Multiple Sclerosis, Progressive Relapsing 71
Progressive-Relapsing Ms 12
Prms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050785
MeSH 44 D020528
SNOMED-CT 67 724778008
UMLS 71 C0393666

Summaries for Progressive Relapsing Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by steadily worsening symptoms and attacks during periods of remission with disease progression from the onset.

MalaCards based summary : Progressive Relapsing Multiple Sclerosis, also known as multiple sclerosis, progressive relapsing, is related to multiple sclerosis and pulmonary aspergilloma. An important gene associated with Progressive Relapsing Multiple Sclerosis is H2AC18 (H2A Clustered Histone 18), and among its related pathways/superpathways are Innate Immune System and Complement and coagulation cascades. The drugs Propranolol and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include heart.

Related Diseases for Progressive Relapsing Multiple Sclerosis

Diseases related to Progressive Relapsing Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Related Disease Score Top Affiliating Genes
1 multiple sclerosis 11.0
2 pulmonary aspergilloma 10.4 FCN3 FCN1
3 borderline leprosy 10.4 MASP2 FCN1
4 rheumatic heart disease 10.4 MBL2 FCN3 FCN2
5 complement component 3 deficiency 10.3 MBL2 MASP1 CFHR2
6 autoimmune disease of urogenital tract 10.3 H2AC18 CFHR2 CCR6
7 blood protein disease 10.3 H2AC18 CFHR2 CCR6
8 gastric squamous cell carcinoma 10.3 SERPINA3 CCR6
9 leprosy 3 10.3 FCN2 FCN1 CCR6
10 mannose-binding lectin deficiency 10.3 MBL2 MASP2 FCN3 FCN1
11 learning disability 10.3 MASP1 H2AC18 COLEC11
12 anti-basement membrane glomerulonephritis 10.3 CFHR2 CCR6
13 spermatogenic failure 50 10.3 TNP2 PRM2 H2AC18
14 dengue disease 10.3 MBL2 IFNB1 H2AC18
15 clear cell chondrosarcoma 10.3 SERPINA3 H2AC18
16 herpes simplex virus keratitis 10.3 IFNB1 CCR6
17 hereditary angioedema 10.3 MBL2 MASP2 MASP1 FCN3
18 ovary adenocarcinoma 10.3 SERPINA3 H2AC18 CFHR2
19 degeneration of macula and posterior pole 10.3 SERPINA3 H2AC18 CFHR2
20 colonic benign neoplasm 10.2 SERPINA3 H2AC18 CCR6
21 anogenital venereal wart 10.2 IFNB1 H2AC18 CCR6
22 sporotrichosis 10.2 MBL2 MASP2
23 acute cystitis 10.2 SERPINA3 H2AC18 CCR6
24 lens disease 10.2 SERPINA3 H2AC18 CFHR2
25 autoimmune disease of skin and connective tissue 10.2 SERPINA3 H2AC18 CCR6
26 invasive aspergillosis 10.2 PTX3 MBL2 CCR6
27 commensal bacterial infectious disease 10.2 SERPINA3 H2AC18 CCR6
28 aspergillosis 10.2 PTX3 MBL2 CCR6
29 herpangina 10.2 IFNB1 H2AC18 CCR6
30 parasitic helminthiasis infectious disease 10.2 SERPINA3 H2AC18 CCR6
31 salivary gland disease 10.2 SERPINA3 H2AC18 CCR6
32 teeth hard tissue disease 10.2 SERPINA3 H2AC18 CCR6
33 spinal cord disease 10.2 IFNB1 H2AC18 CCR6
34 cardiovascular organ benign neoplasm 10.2 SERPINA3 H2AC18 CCR6
35 testicular disease 10.2 SERPINA3 H2AC18 CCR6
36 pre-malignant neoplasm 10.2 SERPINA3 H2AC18 CCR6
37 mental depression 10.2 SERPINA3 H2AC18 CCR6
38 heavy chain disease 10.2 SERPINA3 CFHR2
39 lymphangioma 10.2 SERPINA3 H2AC18 CCR6
40 hypersensitivity reaction type iii disease 10.2 SERPINA3 CFHR2 CCR6
41 panuveitis 10.2 SERPINA3 CFHR2 CCR6
42 bacterial pneumonia 10.2 SERPINA3 H2AC18 CCR6
43 intestinal benign neoplasm 10.2 SERPINA3 H2AC18 CCR6
44 hair disease 10.2 SERPINA3 H2AC18 CCR6
45 chediak-higashi syndrome 10.2 SERPINA3 H2AC18 CCR6
46 streptococcus pneumonia 10.2 IFNB1 CFHR2 CCR6
47 nutritional deficiency disease 10.2 SERPINA3 H2AC18 CCR6
48 cervix carcinoma 10.2 H2AC18 CFHR2 CCR6
49 thyroid gland disease 10.2 SERPINA3 H2AC18 CCR6
50 bone resorption disease 10.2 SERPINA3 H2AC18 CCR6

Graphical network of the top 20 diseases related to Progressive Relapsing Multiple Sclerosis:



Diseases related to Progressive Relapsing Multiple Sclerosis

Symptoms & Phenotypes for Progressive Relapsing Multiple Sclerosis

Drugs & Therapeutics for Progressive Relapsing Multiple Sclerosis

Drugs for Progressive Relapsing Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propranolol Approved, Investigational Phase 4 525-66-6 4946
2
Testosterone Approved, Investigational Phase 4 58-22-0 6013
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
5 Hormone Antagonists Phase 4
6 Hormones Phase 4
7 Androgens Phase 4
8 Citrate Phase 4
9
Morphine Approved, Investigational Phase 1, Phase 2 57-27-2 5288826
10 Narcotics Phase 1, Phase 2
11 Analgesics, Opioid Phase 1, Phase 2
12 Analgesics Phase 1, Phase 2
13 Immunologic Factors Phase 1, Phase 2
14 Vaccines Phase 1, Phase 2
15 Pharmaceutical Solutions Phase 2
16
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
17
tannic acid Approved 1401-55-4

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 Propranolol Reactivation Mismatch (PRM) Treatment for PTSD: A Pilot Study Unknown status NCT03652922 Phase 4 Reactivation Mismatch
2 Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly Completed NCT00018356 Phase 4 testosterone
3 The Effect of Autologous Application of Platelet Rich Plasma on Wound Healing and Pain Perception After Cesarean Section in a Low Resource Setting Completed NCT04669353 Phase 4 Platelet rich plasma
4 A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Recruiting NCT04594707 Phase 3 PRM-151
5 A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis Recruiting NCT04552899 Phase 3 PRM-151;Placebo
6 Changes in Morphine Handling and Response in Patients With Brain Trauma Unknown status NCT00196131 Phase 1, Phase 2 morphine
7 Autologous T Cell Vaccination With Line Specific for 9 Myelin Peptides in Patients With Progressive / Relapsing Multiple Sclerosis Completed NCT01448252 Phase 1, Phase 2
8 A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF) Completed NCT01981850 Phase 2 Ruxolitinib
9 A Randomized, Double-Masked, Placebo-Controlled Study of PRM-151 in the Prevention of Postoperative Scarring in Glaucoma Patients Following Primary Trabeculectomy Completed NCT01064817 Phase 2 PRM-151;Placebo
10 A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT02550873 Phase 2
11 VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents Completed NCT03110770 Phase 2
12 A Randomized, Double-Masked, Sponsor-Unmasked, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRM-151 Administered Intravenously to Patients With Idiopathic Pulmonary Fibrosis Completed NCT01254409 Phase 1
13 An Open-Label, Dose Escalation, Phase I Safety, and Immunogenicity Trial of a Dengue Serotype 1 (DEN-1) Premembrane (prM) and Envelope (E) DNA Vaccine (D1ME100) in Healthy Adults Volunteers Completed NCT00290147 Phase 1
14 Effectiveness and Safety of the Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prospective Phase II Trial Unknown status NCT01910909
15 Pulmonary Recruitment Maneuver With 15 or 30 cmH2O Pressure in Semi-Fowler Position: Which Provides Less Postoperative Shoulder Pain Following Gynecologic Laparoscopic Surgery Completed NCT03970473
16 Effect of Pulmonary Recruitment Maneuver (PRM) on Pain and Nausea After Laparoscopic Bariatric Surgery Completed NCT03026530
17 A Prospective, Blinded, Randomized Clinical Trial Investigating the Effect on Postoperative Pain and Nausea, When Performing a Ventilator-piloted PRM at the End of Laparoscopic Cholecystectomy Completed NCT03026543
18 The Effect of the Informational Manual Therapy for Improving Quiet Standing, Pain and Quality of Life in Healthy Individuals Completed NCT04404829
19 Different Maneuvers for Reducing Post-laparoscopic Shoulder and Abdominal Pain: A Randomized Controlled Trial Recruiting NCT04475809
20 Electroencephalography Activity in Individuals With Nonspecific Chronic Low Back Pain After Cranial Osteopathic Manipulative Treatment: Study Protocol of a Randomized, Controlled Crossover Trial Suspended NCT02111382

Search NIH Clinical Center for Progressive Relapsing Multiple Sclerosis

Genetic Tests for Progressive Relapsing Multiple Sclerosis

Anatomical Context for Progressive Relapsing Multiple Sclerosis

MalaCards organs/tissues related to Progressive Relapsing Multiple Sclerosis:

40
Heart

Publications for Progressive Relapsing Multiple Sclerosis

Articles related to Progressive Relapsing Multiple Sclerosis:

(show all 40)
# Title Authors PMID Year
1
Epidemiology of multiple sclerosis in Santiago de Compostela (Spain). 61
32392359 2020
2
Multiple sclerosis in a multi-ethnic population from Northern California: a retrospective analysis, 2010-2016. 61
32354354 2020
3
Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population. 61
32064117 2020
4
Palliative care interventions for people with multiple sclerosis. 61
31637711 2019
5
Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis. 61
30975397 2019
6
Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009? 61
30815276 2019
7
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. 61
30083762 2018
8
A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis. 61
28365299 2017
9
Multiple sclerosis - etiology and diagnostic potential. 61
28665284 2017
10
Determining Multiple Sclerosis Phenotype from Electronic Medical Records. 61
27882837 2016
11
Bone metabolism and vitamin D status in patients with multiple sclerosis. 61
27375138 2016
12
Recurrent refrains in a patient with multiple sclerosis: Earworms or musical hallucinations? 61
25878018 2014
13
New multiple sclerosis phenotypic classification. 61
25278115 2014
14
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. 61
23841877 2013
15
Teriflunomide for multiple sclerosis. 61
23235682 2012
16
Progressive multiple sclerosis: characteristics and management. 61
21439451 2011
17
Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. 61
20067515 2010
18
[Mitoxantrone for the treatment of patients with multiple sclerosis]. 61
19514518 2009
19
Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. 61
18687447 2008
20
Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. 61
18694542 2008
21
Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. 61
17579804 2007
22
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. 61
17692727 2007
23
Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS). 61
16764339 2006
24
Management of worsening multiple sclerosis with mitoxantrone: a review. 61
16750460 2006
25
Complementary and alternative medicine use in veterans with multiple sclerosis: Prevalence and demographic associations. 61
16847776 2006
26
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. 61
15834643 2005
27
Mitoxantrone for multiple sclerosis. 61
16235298 2005
28
History of modern multiple sclerosis therapy. 61
16170498 2005
29
Mechanism of action of mitoxantrone. 61
15623664 2004
30
Current approved options for treating patients with multiple sclerosis. 61
15623672 2004
31
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. 61
15596747 2004
32
Mitoxantrone for multiple sclerosis in clinical practice. 61
15623666 2004
33
[Immunomodulatory therapy in multiple sclerosis]. 61
15662768 2004
34
Clinical characteristics of progressive relapsing multiple sclerosis. 61
15327045 2004
35
Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. 61
15218811 2004
36
Mitoxantrone: a review of its use in multiple sclerosis. 61
15089110 2004
37
[Diagnosis and treatment of multiple sclerosis. Update, 2003]. 61
14579493 2003
38
A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. 61
12749517 2003
39
Contemporary immunomodulatory therapy for multiple sclerosis. 61
11756861 2001
40
Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. 61
10488816 1999

Variations for Progressive Relapsing Multiple Sclerosis

Expression for Progressive Relapsing Multiple Sclerosis

Search GEO for disease gene expression data for Progressive Relapsing Multiple Sclerosis.

Pathways for Progressive Relapsing Multiple Sclerosis

Pathways related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 SERPINA3 PTX3 MBL2 MASP2 MASP1 IFNB1
2 11.62 MBL2 MASP2 MASP1 CFHR2
3
Show member pathways
11.55 MBL2 MASP2 MASP1 FCN3 FCN2
4 11.53 MBL2 MASP2 MASP1
5
Show member pathways
11.41 MBL2 MASP2 MASP1
6
Show member pathways
11.39 MBL2 MASP2 MASP1 FCN3 FCN2 FCN1

GO Terms for Progressive Relapsing Multiple Sclerosis

Cellular components related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.93 SERPINA3 PTX3 MBL2 MASP2 MASP1 IFNB1
2 extracellular region GO:0005576 9.8 SERPINA3 PTX3 PRB1 MBL2 MASP2 MASP1
3 collagen-containing extracellular matrix GO:0062023 9.73 SERPINA3 MBL2 FCN3 FCN2 FCN1 APCS
4 blood microparticle GO:0072562 9.67 SERPINA3 FCN3 FCN2 APCS
5 nucleosome GO:0000786 9.62 TNP2 PRM3 PRM2 H2AC18
6 collagen trimer GO:0005581 9.1 MBL2 FCN3 FCN2 FCN1 COLEC11 COLEC10

Biological processes related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.04 MBL2 MASP2 MASP1 FCN3 FCN2 FCN1
2 innate immune response GO:0045087 9.81 PTX3 MBL2 MASP2 MASP1 FCN3 FCN2
3 acute-phase response GO:0006953 9.69 SERPINA3 MBL2 APCS
4 negative regulation of viral entry into host cell GO:0046597 9.56 PTX3 FCN3 FCN1 APCS
5 complement activation GO:0006956 9.56 MBL2 MASP2 MASP1 FCN3 FCN2 FCN1
6 negative regulation of viral process GO:0048525 9.54 MBL2 APCS
7 recognition of apoptotic cell GO:0043654 9.54 FCN3 FCN2 FCN1
8 negative regulation by host of viral process GO:0044793 9.52 PTX3 APCS
9 opsonization GO:0008228 9.5 PTX3 MBL2 FCN2
10 negative regulation of glycoprotein metabolic process GO:1903019 9.48 PTX3 APCS
11 negative regulation of exo-alpha-sialidase activity GO:1903016 9.46 PTX3 APCS
12 negative regulation by host of viral glycoprotein metabolic process GO:0044871 9.43 PTX3 APCS
13 negative regulation by host of viral exo-alpha-sialidase activity GO:0044869 9.4 PTX3 APCS
14 complement activation, lectin pathway GO:0001867 9.23 MBL2 MASP2 MASP1 FCN3 FCN2 FCN1

Molecular functions related to Progressive Relapsing Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virion binding GO:0046790 9.37 PTX3 APCS
2 mannose binding GO:0005537 9.33 MBL2 COLEC11 COLEC10
3 complement component C1q binding GO:0001849 9.32 PTX3 APCS
4 carbohydrate derivative binding GO:0097367 9.26 FCN2 FCN1
5 calcium-dependent protein binding GO:0048306 9.26 MBL2 MASP2 MASP1 FCN2
6 carbohydrate binding GO:0030246 9.17 MBL2 FCN3 FCN2 FCN1 COLEC11 COLEC10

Sources for Progressive Relapsing Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....